非肽类促性腺激素释放激素拮抗剂在子宫肌瘤治疗中的应用研究进展OA北大核心CSTPCD
Progress in the application of non-peptide gonadotropin-releasing hormone antagonist in the treatment of uterine fibroid
非肽类促性腺激素释放激素拮抗剂(go-nadotropin-releasing hormone antagonist,GnRH-antagonist)作为GnRH受体的一种高效、选择性拮抗剂,其口服制剂(Elagolix,Relugolix及Linzago-lix)已在国外获批上市,在用于子宫肌瘤缩小肌瘤体积、控制月经过多等方面展示了一定疗效,适当配伍反加治疗可以提高药物安全性与患者依从性,相比其他激素类制剂,口服GnRH拮抗剂在子宫肌瘤治疗中展示了良好的应用前景.
Non-peptide gonadotropin-releasing hormone antagonist(GnRH-antagonist)is a highly efficient and selective antagonist of GnRH receptor.The oral preparations(Elagolix,Relugolix and Linza-golix)had been approved for listing abroad.It shows efficacy in reducing the size of uterine fi-broid and controlling heavy bleeding.Appropriate combination of'add-back'therapy could improve the safety in medical application and patient com-pliance.Compared with other hormonal pharma-ceuticals,oral GnRH-antagonists showed promising prospects in the treatment of uterine fibroid.
郑韵熹;易晓芳;徐丛剑
复旦大学附属妇产科医院,上海 200011
临床医学
促性腺激素释放激素拮抗剂子宫肌瘤治疗有效性安全性
gonadotropin releasing hormone an-tagonistsuterine fibroidtreatmenteffectivenesssafety
《中国临床药理学与治疗学》 2024 (005)
482-487 / 6
国家重点研发计划"生育健康及妇女儿童健康保障"重点专项(2022YFC2704000)
评论